PTIXOTCPharmaceutical PreparationsFiscal year ends March 31

Protagenic Therapeutics, Inc.\new

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026

$0.75+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $1.36M
P/E (TTM): –
Dividend yield: –

Protagenic Therapeutics, Inc.\new balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2014 2014-06-30	FY 2013 2013-06-30
Cash & Equivalents	0.08	1.29	0.22	0.54	0.67	0.80	0.36	0.40	3.10	0.10	0.72
Short-Term Investments	–	2.77	7.76	9.83	–	–	–	–	–	–	–
Cash & Short-Term Investments	0.08	4.06	7.98	10	0.67	0.80	0.36	0.40	3.10	0.10	0.72
Prepaid Expenses & Other	0.04	0.14	0.06	0.69	0.21	0.04	0.08	0.09	0.06	0.14	–
Total Current Assets	1.88	4.20	8.04	11	0.88	0.84	0.70	1.78	3.16	0.25	–
Property, Plant & Equipment	0.07	0.12	0.00	–	–	0.00	0.00	0.00	0.00	0.00	–
Accumulated Depreciation	–	–	–	–	–	–	–	–	–	0	–
Total Assets	1.96	4.32	8.04	11	0.88	0.84	0.70	1.78	3.16	0.25	–
Accounts Payable	–	–	0.67	0.50	0.57	0.87	0.23	0.14	0.17	0.14	–
Total Current Liabilities	0.94	0.66	1.12	0.80	0.66	1.20	0.91	0.56	0.68	0.14	–
Long-Term Debt	–	–	–	–	–	–	–	–	–	0.18	–
Total Liabilities	0.94	0.66	1.12	1.12	2.03	1.48	0.91	0.56	0.68	0.32	–
Total Debt	–	–	–	–	–	–	–	–	–	0.18	–
Preferred Stock	–	–	–	–	–	–	–	–	–	0.01	–
Common Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0	–
Additional Paid-In Capital	37	35	33	32	17	15	13	12	11	1.05	–
Retained Earnings	-36	-31	-26	-22	-18	-15	-13	-11	-8.58	-1.08	–
Treasury Stock	–	–	–	–	–	–	–	–	–	0	–
Comprehensive Income & Other	-0.13	-0.11	-0.68	-0.25	-0.17	-0.17	-0.17	-0.17	-0.18	–	–
Shareholders' Equity	-3.32	3.67	6.92	9.94	-1.15	-0.63	-0.21	1.22	2.48	-0.02	–
Noncontrolling Interest	–	–	–	–	–	–	–	–	–	-0.05	–
Total Equity	-3.32	3.67	6.92	9.94	-1.15	-0.63	-0.21	1.22	2.48	-0.07	–
Total Liabilities & Equity	1.96	4.32	8.04	11	0.88	0.84	0.70	1.78	3.16	0.25	–
Shares Outstanding(shares)	0.52	0.32	0.31	0.31	0.19	0.18	0.18	0.18	0.18	0.12	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2024: -3157.4%

Financial strength

Current ratio: 0.66
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 52.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.79
Dividend yield: –